ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: interstitial lung disease

ACR/ARHP Annual Scientific Meeting Plenary Highlights Targets and Treatments for Several Diseases

  |  

Promising therapeutic targets for rheumatic diseases were the focus of a plenary session here at the ACR/ARHP 2011 Annual Scientific Meeting in November. Presenters discussed discoveries and treatments for systemic sclerosis, rheumatoid arthritis, vasculitis, and Behçet’s disease.

Air Pollution May Increase the Risk of RA & RA-Associated ILD

  |  

Exposure to air pollution, such as high levels of particulate matter from fire smoke and fossil fuel-related nitrogen oxides, may increase the risk of rheumatoid arthritis (RA) and RA-associated interstitial lung disease (ILD), according to Kronzer et al. Their findings highlight the need for improved monitoring of air pollutants and suggest that addressing air pollution may help prevent RA and RA-associated ILD.

Editor's Pick

The ACR and CHEST Release 2 New ILD Guidelines

  |  

Clinicians should not rely on glucocorticoids as a first-line treatment of SARD-ILD in patients with systemic sclerosis, according to a strong recommendation in a new ILD treatment guideline from the ACR and CHEST. The guideline is one of two addressing the screening, monitoring and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs).

A Combined Immunosuppressive Regimen for ILD MDA5-Positive Dermatomyositis

  |  

Interstitial lung disease accompanied by anti-melanoma differentiation-associated gene 5 positive dermatomyositis is often rapidly progressive and associated with poor prognosis. In this study, a combined immunosuppressive regimen of high-dose glucocorticoids, tacrolimus and intravenous cyclophosphamide proved more effective than treatment with high-dose glucocorticoids and stepwise addition of an immunosuppressant in a historical control group.